Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer

医学 贝伐单抗 西妥昔单抗 伊立替康 肿瘤科 结直肠癌 临床终点 内科学 原发性肿瘤 奥沙利铂 癌症 不利影响 疾病 化疗 临床试验 转移
作者
Matthew Snyder,Sal Bottiglieri,Khaldoun Almhanna
出处
期刊:Reviews on Recent Clinical Trials [Bentham Science Publishers]
卷期号:13 (2): 139-149 被引量:24
标识
DOI:10.2174/1574887113666180328104109
摘要

Background: Colorectal cancer is one of the most common malignancies in the United States, with a large proportion of patients presenting with metastatic disease or developing a recurrence. Systemic chemotherapy is the mainstay of therapy in this setting. There is a clear benefit in the addition of bevacizumab or cetuximab (for rat sarcoma [RAS] wild type tumors) to oxaliplatin- and irinotecan-based regimens which can be considered for first-line therapy. However, many significant questions remain as to which agent reflects best practice. Objective: Our review aimed to elucidate the benefit of adding bevacizumab and cetuximab to initial therapy for metastatic colorectal cancer based on primary tumor location and a variety of other disease- and patient-related factors, addressing the paucity of evidence that currently exists in this area and contributing to current literature and clinical practices. Methods: The primary endpoints of the study were first Progression-Free Survival (PFS) and Overall Survival (OS). Secondary endpoints included best response to first- and second-line therapies, Treatment- Related Adverse Events (TRAEs), second PFS, cost of therapy, and an assessment of other patient- and disease-related factors affecting PFS and OS. Results: While there were trends towards improved OS in patients with left-sided primary tumors (n=57) compared to those with right-sided disease (n=23), there were no significant differences between the two groups in either primary endpoint. While no differences were found for patients with left- or right- sided tumors stratified by add-on agent, these analyses were limited by the small number of patients receiving cetuximab with first-line therapy (n=4). However, the bevacizumab cohort (n=76) was sizable enough to provide ample data and produce clinically relevant results. Add-on therapy with bevacizumab in our study achieved impressive survival outcomes in both left-sided (median first PFS = 13 months, 95% CI 11-15 months; median OS = 37 months, 95% CI 21-53 months) and right-sided (median first PFS = 13 months, 95% CI 9-17 months; median OS = 37 months, 95% CI 22-52 months) disease. Conclusion: These results raised questions regarding the true significance of primary tumor location when selecting bevacizumab or cetuximab for first-line therapy, particularly the current thought of using cetuximab for left-sided tumors. While the superiority of bevacizumab over cetuximab in rightsided disease remained evident upon comparison of our analysis with historical controls, survival outcomes with the agent in our analysis appeared to be similar to that of cetuximab in CRYSTAL, FIRE- 3, and CALGB/SWOG 80405 in left-sided disease. Further study is required to determine if bevacizumab truly does produce similar outcomes to cetuximab in left-sided primary tumors. Keywords: Bevacizumab, cetuximab, left-sided tumors, metastatic colorectal cancer, primary tumor location, right-sided tumors, targeted therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
归尘发布了新的文献求助10
1秒前
Nnn发布了新的文献求助100
1秒前
catalysisman完成签到,获得积分10
1秒前
十八完成签到,获得积分10
1秒前
fvsuar完成签到,获得积分10
2秒前
2秒前
初一完成签到,获得积分10
2秒前
fj发布了新的文献求助10
3秒前
香蕉觅云应助沉默的尔槐采纳,获得10
3秒前
JamesPei应助骆風采纳,获得10
3秒前
andrewyu发布了新的文献求助10
3秒前
喜悦的丹妗完成签到,获得积分20
4秒前
阿冰发布了新的文献求助10
4秒前
5秒前
大方板栗完成签到,获得积分10
5秒前
科研圣体发布了新的文献求助10
5秒前
5秒前
聪慧芷巧发布了新的文献求助10
6秒前
方不慌完成签到,获得积分10
6秒前
宋子琛发布了新的文献求助10
7秒前
畅快的觅风完成签到,获得积分20
7秒前
852应助吃点红糖馒头采纳,获得10
7秒前
7秒前
8秒前
江江江完成签到,获得积分20
9秒前
煎饼煎饼发布了新的文献求助10
9秒前
脑洞疼应助风清扬采纳,获得10
10秒前
10秒前
Cartman完成签到,获得积分10
10秒前
共享精神应助vicky采纳,获得10
11秒前
欢呼的鲂完成签到,获得积分10
11秒前
11秒前
甜美冰旋完成签到,获得积分20
11秒前
12秒前
12秒前
13秒前
江江江发布了新的文献求助10
13秒前
石石石完成签到,获得积分10
13秒前
淡淡的炳发布了新的文献求助10
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974779
求助须知:如何正确求助?哪些是违规求助? 3519193
关于积分的说明 11197417
捐赠科研通 3255311
什么是DOI,文献DOI怎么找? 1797760
邀请新用户注册赠送积分活动 877150
科研通“疑难数据库(出版商)”最低求助积分说明 806187